Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma.

ABSTRACT:

Background

Despite the acknowledged sex-related differences in immune response and immune checkpoint inhibitor (ICI) efficacy, little is known about the sex disparities in melanoma of novel genomic determinants for ICI therapies.

Methods

Pretreatment genomic profiles and clinical characteristics of 631 melanoma patients treated with ICIs (i.e., inhibitors of CTLA-4, PD-1/PD-L1, or both) were comprehensively curated. Genomic factors, i.e., significantly mutated genes (SMGs), mutational signatures, and molecular subtypes were identified, and their associations with ICI treatment efficacy in male and female patients were evaluated.

Results

Of the 15 SMGs identified in this study, three genes (i.e., CFH, DGKG, and PPP6C) were found to exhibit sex diff

SUBMITTER: Shi F 

PROVIDER: S-EPMC8594267 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature